Early Tecovirimat Treatment for Mpox Disease Among People With HIV

Cohort study (n=112 people with HIV) found those treated with tecovirimat within 7 days of mpox symptom onset were less likely to progress to severe mpox disease than those treated after 7 days or untreated (paired odds ratio 13.00, 95% CI, 1.71-99.40; P = 0.002).

SPS commentary:

Authors conclude findings of the study support the use of this antiviral that inhibits viral envelope protein p37, in all people with HIV as soon as mpox is suspected.

A related commentary discusses the study and its findings. It notes that the authors’ conclusions may be premature and should be tempered given the observational nature of the evidence and the limitations of tecovirimat availability. It addresses these issues in greater detail and calls for definitive efficacy data via a randomised clinical trial.

JAMA Internal Medicine

Resource links:

Commentary